Data from Pharmawand - Curated by EPG Health - Date added 14 November 2017
Theravance Biopharma, Inc. and Mylan N.V. announced the submission of a New Drug Application (NDA) to the FDA for revefenacin (TD 4208), an investigational long-acting muscarinic antagonist (LAMA) as a once-daily, nebulized bronchodilator in development for the treatment of chronic obstructive pulmonary disease (COPD).
The NDA is supported by the companies' Phase III program for revefenacin, which consisted of two replicate pivotal Phase III efficacy studies and a 12-month, open-label, active comparator safety study.
Comment:This submission represents a key step in efforts to bring the first once-daily nebulized LAMA to the COPD patient community. While a significant number of COPD patients require or prefer nebulized therapy, these same patients currently have no access to a nebulized LAMA, broadly considered the cornerstone of COPD maintenance therapy.
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Chronic Obstructive Pulmonary Disease (COPD)
View highlights from recent congresses presented in new expert videos with leading physicians.
+ 7 more
Allergic Rhinitis
Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.
+ 4 more
Cystic Fibrosis Knowledge Centre
View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.
Related Content
FDA advisory committee negative recommendation for mepolizumab as an add-on treatment for the reduction of exacerbations in patients with COPD.- GSK.
GlaxoSmithKline plc announced the outcome of the Pulmonary Allergy Drugs Advisory Committee of the FDA meeting on the use of...
Added 19 days ago
Fasenra fails Phase III TERRANOVA trial for COPD.- AstraZenaca
AstraZeneca and MedImmune, its global biologics research and development arm, announced top-line results from TERRANOVA, the second of two pivotal...
Added 2 months ago
IMPACT study of Trelegy Ellipta in COPD published in NEJM.- GlaxoSmithKline + Innoviva.
GlaxoSmithKline and Innoviva announced the publication in the New England Journal of Medicine (NEJM) of the landmark IMPACT study, one...
Added 3 months ago
DYNAGITO trial results of Stiolto Respimat in chronic obstructive pulmonary disease published in The Lancet Respiratory Medicine.- Boehringer.
Boehringer announced that data from the DYNAGITO trial, a 52-week study involving more than 7,800 people across a broad range...
Added 4 months ago
Comments
You will need to login, to leave a comment.
epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.